From modeling the capital impact of the proposed factors across the ten largest PE-backed life carriers, the delta between current and proposed charges on below-investment-grade CLO tranches ranges from 4x to 26x. That is not a rounding error. It is a structural repricing of the risk-based capital framework that will force portfolio repositioning, test surplus adequacy, and potentially reshape the competitive dynamics between PE-affiliated and traditional life insurers.

The NAIC's RBC Investment Risk and Evaluation Working Group discussed the Academy's CLO modeling framework at the Spring 2026 National Meeting in Kansas City on March 22-25. The proposed factors emerged from a multi-year analytical project that modeled over 2,600 broadly syndicated loan (BSL) CLO deals using a conditional tail expectation (CTE) 90 methodology consistent with existing C-1 bond factors. The results split cleanly: investment-grade tranches at the top of CLO capital structures carry minimal risk charges, while junior tranches and thin positions face charges that dwarf their current treatment.

This analysis unpacks the proposed factor framework, models the capital impact on PE-backed portfolios, connects the CLO initiative to the parallel collateral loan and transparency reforms, and assesses the implementation timeline that actuaries must prepare for.

The Proposed CLO Capital Factor Framework

The Academy presented two alternative sets of modeled CLO C-1 factors to the NAIC. The first set relies on ratings alone. The second incorporates both ratings and tranche thickness for tranches rated Baa3 and below. Both sets use CTE(90) as the tail metric, running 10,000 default and recovery scenarios to generate loss distributions consistent with the existing C-1 bond factor methodology.

Under the ratings-only approach, investment-grade tranches (Aaa through Baa3) carry factors ranging from 0.03% to 2.73%. That range aligns with or falls below current bond factors for comparable ratings, reflecting the structural protections that senior CLO tranches enjoy: overcollateralization, interest coverage triggers, waterfall priority, and portfolio diversification across 150 to 300 underlying leveraged loans.

Below investment grade, the picture inverts. Factors range from 12.59% to 70.82%, reflecting the cliff risk that junior tranches face when collateral losses breach structural protections. The Academy's modeling confirmed what practitioners have long observed: CLO structures concentrate loss volatility in the lowest tranches, where small changes in portfolio default rates produce disproportionate principal impairment.

Rating Category Proposed C-1 Factor (Ratings Only) Current Bond Factor (Approximate) Ratio: Proposed vs. Current
Aaa 0.03% 0.40% 0.08x (lower)
Aa 0.06% 0.40% 0.15x (lower)
A 0.14% 0.75% 0.19x (lower)
Baa (thick tranche) 2.73% 2.00% 1.4x
Baa (thin tranche, <4%) 12.52% 2.00% 6.3x
Ba 12.59% 4.60% 2.7x
B ~35% 10.00% 3.5x
Caa and below 70.82% 23.00% 3.1x

Note: Current bond factors shown are approximate C-1 factors from NAIC RBC instructions. Proposed factors from Academy of Actuaries modeling presented to RBCIREWG at Spring 2026 National Meeting. The "thin tranche" Baa factor applies when the tranche represents less than 4% of CLO deal capital structure.

The Tranche Thickness Multiplier

The most consequential design choice in the Academy's framework is the tranche thickness adjustment. Under Option 2 of the proposed factors, a Baa3-rated CLO tranche that represents less than 4% of the deal's capital structure faces a charge of 12.52%, compared to 2.73% for a thick Baa3 tranche. That is a 4.6x penalty for structural thinness alone.

The actuarial logic is straightforward: thin tranches have less absolute dollar cushion before principal impairment. A Baa3 tranche representing 8% of a CLO's capital structure absorbs eight cents of collateral loss per dollar of deal notional before facing writedowns. The same rating on a 3% tranche absorbs only three cents. The CTE(90) tail scenarios capture this differential precisely because the loss distributions are non-linear at the tranche boundaries.

The 4% threshold (with the NAIC also considering 4.25%) creates a bright line that will drive structuring decisions. CLO managers seeking insurance company investors will face incentives to maintain tranche thickness above 4%, potentially constraining deal flexibility and limiting the issuance of mezzanine tranches favored by yield-seeking PE-backed portfolios.

The Academy noted it has not yet had sufficient time to address recoveries, prepayments, default probabilities in stress scenarios, and middle-market CLOs. Middle-market CLOs represent approximately 20% of the CLO universe but use unrated underlying loans, complicating factor development. This gap matters because several PE-backed life insurers hold meaningful middle-market CLO exposure through affiliated managers.

PE-Backed Portfolios: Modeling the Capital Impact

PE-backed life insurers hold disproportionate concentrations of CLOs and structured securities. Industry data shows that PE-owned annuity platforms allocate approximately 25% of invested assets to CLOs and asset-backed securities, compared to 10-15% for traditional mutual life insurers. At Athene (Apollo-affiliated), roughly 25% of cash and investments sit in CLO and ABS positions, up from 10% a decade earlier. Global Atlantic, now part of KKR, holds comparable concentrations through affiliated Schedule D assets totaling approximately $24 billion.

The industry-wide data confirms the trend: ABS and CLO holdings across the life insurance sector grew 12% year over year through 2025, with PE-backed carriers driving the acceleration. Total life insurer deployment into private credit strategies reached an estimated $180 billion in 2025, up from $120 billion in 2023.

To model the capital impact, consider a stylized PE-backed life insurer with $80 billion in general account assets, 25% allocated to CLOs and structured credit ($20 billion), of which 15% ($3 billion) sits in below-investment-grade tranches or thin mezzanine positions. Under current bond factors averaging approximately 5% for this mix, the C-1 charge on the sub-IG CLO portfolio equals $150 million. Under the proposed factors averaging 30% for the same mix (blending Ba at 12.59%, B at ~35%, and thin Baa positions at 12.52%), the charge rises to $900 million.

That $750 million capital increase represents approximately 200-300 basis points of RBC ratio compression, depending on the insurer's total adjusted capital (TAC) position. For a carrier running at 350% company action level RBC, this single change could push the ratio below 300%, triggering heightened regulatory scrutiny and potentially requiring capital injections from the PE sponsor.

Carrier Profile Estimated CLO/ABS Allocation Sub-IG Exposure Estimated Capital Increase
Large PE-backed ($80B GA) $20B (25%) $3B $600M-$900M
Mid-size PE-backed ($30B GA) $7.5B (25%) $1.1B $225M-$340M
Traditional mutual ($100B GA) $12B (12%) $0.6B $90M-$150M

Estimates assume blended proposed factor of 25-35% on sub-IG and thin-tranche positions versus current blended factor of approximately 5%. Actual impact depends on precise tranche-level holdings data from Schedule D filings.

The differential impact is clear: PE-backed carriers face 4x to 6x the absolute capital increase of traditional insurers, a function of both higher CLO concentration and greater exposure to the below-investment-grade tranches where the factor increases are largest.

Collateral Loan Capital Charges: The Parallel Track

Running alongside the CLO factor project is Proposal 2025-16-L MOD on collateral loans. The Life RBC Working Group re-exposed this proposal at the Spring meeting with a 23-day public comment period ending April 13, 2026. The proposal establishes differentiated capital charges based on the collateral backing the loan, rejecting the "look-through" approach that would trace capital charges to the ultimate underlying assets.

The proposed collateral loan factors:

  • Mortgage loans backing collateral loans: 3% (consistent with existing mortgage loan factors)
  • Equity interests in JVs, partnerships, and LLCs: 30% (up from the current blanket 6.8%)
  • Residual tranches: 45% (consistent with the 2024 adoption for residual interests)
  • All other collateral types: 6.8% (maintaining the current default factor)

The 30% charge on equity interests in joint ventures represents a 4.4x increase from the current 6.8% blanket rate. This matters for PE-backed insurers because collateral loans backed by fund interests, partnership stakes, and LLC equity are a common mechanism for deploying capital into affiliated private credit vehicles. A PE-affiliated life insurer with $5 billion in collateral loans backed by fund equity interests faces a capital charge increase from $340 million (at 6.8%) to $1.5 billion (at 30%), a $1.16 billion swing.

The proposal also incorporates an asset concentration factor that doubles charges, subject to a 45% cap. This provision targets single-counterparty and single-sector concentrations that characterize affiliated investment structures. A generic 20% haircut would be applied as a calibration adjustment, reducing the raw 30% to an effective 24% for collateral loans backed by JV/LLC equity and reducing the 45% to an effective 36% for residual tranches.

Implementation timing for collateral loans has slipped to year-end 2027, with regulators and industry commenters agreeing that empirical support and adequate transition runway justify the delay. The NAIC commissioners specifically opposed a year-end 2026 effective date, citing the need for data-driven analysis and proportional charges.

The Transparency Push: Private Ratings and Related-Party Reporting

The capital charge reforms do not exist in isolation. The NAIC has simultaneously advanced two transparency initiatives that compound the regulatory pressure on PE-backed structures.

Private rating letter rationale reports. The NAIC now requires that private rating entities file rationale reports with the Securities Valuation Office (SVO) within 90 days of a rating action. These reports must contain sufficient analytical substance to justify the assigned rating. Securities without a compliant rationale report become ineligible for the filing-exempt (FE) process until the SVO receives adequate documentation.

This requirement targets a specific PE-backed insurer practice: using private ratings from Egan-Jones, KBRA, or DBRS to assign NAIC designations to bespoke structured securities without the analytical transparency that public ratings from S&P, Moody's, or Fitch provide. Since January 1, 2024, privately-rated securities have generally required a corresponding rationale report for FE eligibility. The 90-day enforcement mechanism adds teeth: miss the deadline and the security drops out of FE, requiring SVO modeling that may produce a less favorable designation.

Related-party transaction reporting codes. Adopted in 2022 and now fully operational, these codes require insurers to identify the role of related parties in investment schedules. The reporting framework addresses the opacity of fee structures in PE-affiliated investment management arrangements where advisory fees, performance allocations, transaction costs, and origination charges flow between the insurer and its private equity sponsor through multiple entities.

The combined effect of these three tracks (CLO capital charges, private rating transparency, and related-party reporting) creates what Clifford Chance characterized as the NAIC's "evolving response" to private equity in insurance. Regulators have deliberately avoided PE-specific rules, instead advancing broad reforms that apply to all insurers but whose practical impact concentrates on PE-affiliated structures.

Implementation Timeline: What Actuaries Must Prepare For

The timeline splits across three workstreams with different effective dates:

Workstream Comment Deadline Target Adoption Effective Date
CLO RBC Structure (instructions) April 17, 2026 Summer 2026 December 31, 2026
CLO Risk Factors (Academy model) April 16, 2026 Late 2026 December 31, 2026 (may slip to 2027)
Collateral Loan Factors (2025-16-L MOD) April 13, 2026 Late 2026 December 31, 2027
Private Rating Letter 90-Day Rule Already adopted In effect Currently enforced

The structural RBC instruction changes require May adoption for a year-end 2026 effective date, while the actual capital factors can be adopted later under the existing framework. J.P. Morgan Asset Management noted that this sequencing permits ongoing discussion of the factor calibration even after the structural framework is locked. However, this creates uncertainty for year-end 2026 RBC projections: actuaries may know the calculation framework but not the final factors until Q3 or Q4.

From tracking prior NAIC multi-year capital projects (the bond factor update took three years from initial proposal to full adoption), we expect the CLO factors to land in phases. Senior investment-grade factors (Aaa through A) face minimal controversy and could adopt on schedule. The below-investment-grade factors and the tranche thickness adjustment remain contentious and may slip to 2027 year-end, aligning with the collateral loan timeline.

Actuarial Reserving and Portfolio Strategy Implications

The capital charge increases create immediate work for life actuaries across three domains:

1. Asset adequacy testing (AAT). Under AG 55 and VM-30, life actuaries conducting asset adequacy analysis must consider the regulatory capital context. Higher RBC charges on CLO positions change the effective yield available after capital costs. An asset returning SOFR + 250 bps with a 2% capital charge produces a fundamentally different risk-adjusted return than the same asset with a 12% or 30% capital charge. Appointed actuaries must recalibrate their cash flow testing assumptions for CLO-heavy portfolios.

2. Surplus strain projections. For PE-backed carriers running dynamic financial analysis (DFA) models, the proposed factors require re-parameterization of the capital adequacy module. The non-linear relationship between CLO ratings migration and capital charges (a one-notch downgrade from Baa3 to Ba1 produces a 4.6x factor jump under the thickness-adjusted approach) creates tail scenarios that current DFA models likely underestimate.

3. Portfolio rebalancing under ASOP No. 7. The Statement of Actuarial Opinion for life insurers under ASOP No. 7 (Analysis of Life, Health, or Property/Casualty Insurer Cash Flows) requires the actuary to consider capital market conditions affecting the insurer's investment strategy. A material change in RBC factors constitutes such a condition. Actuaries must assess whether current portfolio allocations remain appropriate under the revised capital framework, particularly for affiliated investments where the actuary's independence may face scrutiny.

PE sponsors face a strategic choice: absorb the capital hit and maintain current allocations (requiring fresh equity injections), or rebalance portfolios away from below-investment-grade and thin-tranche CLO positions toward the senior tranches where proposed factors actually decrease. The Academy's finding that Aaa through A2 factors fall below current bond factors creates a regulatory incentive to move up the capital structure, even at lower yields.

The Broader NAIC Investment Framework Context

The CLO and collateral loan projects represent two pieces of a larger mosaic. In 2024, the NAIC adopted the Insurer Investment Framework to ensure regulatory capital keeps pace with how insurers are deploying assets. Concurrent initiatives include:

  • Investment subsidiary RBC elimination: The Capital Adequacy (E) Task Force exposed a proposal in April 2026 to delete the investment subsidiary category from RBC blanks, forcing these assets through standard factor-based charges rather than the subsidiary look-through. This compounds the CLO impact for carriers that held CLO portfolios through subsidiary structures.
  • SSAP 109 (ALM derivatives): New statutory accounting guidance allowing amortized cost treatment for qualifying interest rate derivatives used in macro-hedging programs. Comments were due May 1, 2026, with a January 1, 2027 potential effective date. This partially offsets the CLO capital hit by reducing balance sheet volatility from ALM hedges.
  • Negative IMR proof-of-reinvestment: Adopted at Spring 2026 (Ref #2025-23), this requires insurers to demonstrate that bond and loan acquisitions match sold fixed-income investments with weighted average yields exceeding sales proceeds. The reinvestment test constrains the ability to sell CLO positions and redeploy without meeting yield benchmarks.
  • RBC Model Governance Task Force (RBCMGTF) gap analysis: The task force identified inconsistencies across Life, P&C, and Health formulas, including insufficient recognition of illiquidity risk, interest rate risk, and spread duration risk. These gaps will generate additional factor revisions in 2027-2028.

Patterns we have seen across NAIC capital reform cycles suggest that initial factor proposals moderate during comment periods but rarely reverse direction. The bond factor update (adopted 2021, phased implementation through 2024) saw approximately 15-20% compression in proposed factors for investment-grade but maintained the directional shift for high-yield. We expect a similar dynamic here: investment-grade CLO factors may decrease slightly while below-investment-grade factors hold at or near proposed levels.

Middle-Market CLOs: The Unresolved Gap

The Academy explicitly acknowledged that its modeling covers only broadly syndicated loan CLOs. Middle-market CLOs, representing approximately 20% of the CLO universe, use unrated underlying loans that lack the default and recovery data available for BSL CLOs. Several PE-backed life insurers hold significant middle-market CLO exposure through affiliated managers who originate the underlying loans.

Until the Academy develops middle-market CLO factors (no timeline announced), these positions may default to either the BSL factors (potentially inappropriate given different collateral characteristics) or the collateral loan factors (potentially punitive at 6.8% to 30% depending on structure). This regulatory gap creates uncertainty that actuaries must address in year-end opinions through conservatism in capital projections.

The middle-market gap also intersects with the private rating letter requirement. Many middle-market CLO tranches carry private ratings precisely because the underlying pools lack public market pricing and observable default data. The 90-day rationale report requirement adds documentation burden but does not resolve the fundamental question of whether private ratings adequately capture tail risk in less liquid, less transparent loan pools.

Why This Matters for Life Actuaries

This is not a rulemaking exercise that actuaries can monitor from a distance. The CLO capital overhaul directly affects the actuarial opinion, asset adequacy conclusions, surplus projections, and strategic asset allocation advice that life actuaries deliver to their boards and regulators.

For appointed actuaries at PE-backed carriers, the 2026 asset adequacy analysis will need to incorporate scenario testing under both current and proposed factors, since the effective date may or may not land on the December 31, 2026 reporting date. The ASOP No. 7 requirement to consider "known conditions" includes pending regulatory changes of this magnitude.

For consulting actuaries advising PE sponsors on insurance acquisitions or de-risking transactions, the proposed factors change the calculus of which asset allocations remain viable under the revised capital framework. A PE sponsor evaluating a life insurance platform acquisition must now model a capital regime where 25% CLO allocations at below-investment-grade carry fundamentally different economics than they did under the legacy bond factor approach.

For actuaries at traditional life insurers competing against PE-backed platforms for pension risk transfer (PRT) and annuity business, the proposed factors may narrow the yield advantage that PE-backed carriers have leveraged through higher CLO allocations. If below-investment-grade CLO charges rise from 5% to 30%, the capital-adjusted spread narrows significantly, potentially leveling the competitive field in PRT pricing.

The NAIC has signaled clearly that the era of treating CLO tranches like comparable-rated corporate bonds is ending. The only remaining questions are calibration precision and implementation timing. Actuaries who wait for final adoption to begin their analysis will be six months behind those who start modeling now.

Further Reading

Sources